Terms: = Prostate cancer AND TMPRSS2, PRSS10, 7113, ENSG00000184012, O15393 AND Treatment
229 results:
1. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
2. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
3. Antagonism of androgen receptor signaling by aloe-emodin.
Zhao J; Sun Y; Ren L; Huang S; Zhang J
Food Chem Toxicol; 2023 Nov; 181():114092. PubMed ID: 37806336
[TBL] [Abstract] [Full Text] [Related]
4. Club-like cells in proliferative inflammatory atrophy of the prostate.
Huang FW; Song H; Weinstein HN; Xie J; Cooperberg MR; Hicks J; Mummert L; De Marzo AM; Sfanos KS
J Pathol; 2023 Sep; 261(1):85-95. PubMed ID: 37550827
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
6. The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Pernigoni N; Guo C; Gallagher L; Yuan W; Colucci M; Troiani M; Liu L; Maraccani L; Guccini I; Migliorini D; de Bono J; Alimonti A
Nat Rev Urol; 2023 Dec; 20(12):706-718. PubMed ID: 37491512
[TBL] [Abstract] [Full Text] [Related]
7. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Qiao Y; Wotring JW; Zheng Y; Zhang CJ; Zhang Y; Jiang X; Pretto CD; Eyunni S; Parolia A; He T; Cheng C; Cao X; Wang R; Su F; Ellison SJ; Wang Y; Qin J; Yan H; Zhou Q; Ma L; Sexton JZ; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2221809120. PubMed ID: 37459541
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptome Profiling of prostate cancer, Considering Risk Groups and the tmprss2-ERG Molecular Subtype.
Kobelyatskaya AA; Pudova EA; Katunina IV; Snezhkina AV; Fedorova MS; Pavlov VS; Kotelnikova AO; Nyushko KM; Alekseev BY; Krasnov GS; Kudryavtseva AV
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298233
[TBL] [Abstract] [Full Text] [Related]
9. The performance and limitations of PCA3, tmprss2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
[TBL] [Abstract] [Full Text] [Related]
10. Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
Majidipur A; Morin-Dewaele M; Gaspar Lopes J; Berry F; Fouchet J; Bartier S; Dufros Duval A; Soyeux P; Huet E; Louis B; Coste A; Béquignon É; Saldana C; Le Corvoisier P; Destouches D; Pawlotsky JM; de la Taille A; Vacherot F; Bruscella P; Firlej V
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834705
[TBL] [Abstract] [Full Text] [Related]
11. Nifuroxazide Activates the Parthanatos to Overcome tmprss2:ERG Fusion-Positive prostate cancer.
Li C; Zhang J; Wu Q; Kumar A; Pan G; Kelvin DJ
Mol Cancer Ther; 2023 Mar; 22(3):306-316. PubMed ID: 36622760
[TBL] [Abstract] [Full Text] [Related]
12. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Fernandez-Perez MP; Perez-Navarro E; Alonso-Gordoa T; Conteduca V; Font A; Vázquez-Estévez S; González-Del-Alba A; Wetterskog D; Antonarakis ES; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez Sanchez A; Santander C; Sáez MI; Puente J; Tudela J; Martínez A; López-Andreo MJ; Padilla J; Lozano R; Hervas D; Luo J; de Giorgi U; Castellano D; Attard G; Grande E; Gonzalez-Billalabeitia E
Prostate; 2023 Mar; 83(4):376-384. PubMed ID: 36564933
[TBL] [Abstract] [Full Text] [Related]
13. Differences in prostate cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?
Zhou CD; Pettersson A; Plym A; Tyekucheva S; Penney KL; Sesso HD; Kantoff PW; Mucci LA; Stopsack KH
Cancer Prev Res (Phila); 2022 Dec; 15(12):815-825. PubMed ID: 36125434
[TBL] [Abstract] [Full Text] [Related]
14. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract] [Full Text] [Related]
15. α-Terthienyl induces prostate cancer cell death through inhibiting androgen receptor expression.
Gan X; Huang H; Wen J; Liu K; Yang Y; Li X; Fang G; Liu Y; Wang X
Biomed Pharmacother; 2022 Aug; 152():113266. PubMed ID: 35691152
[TBL] [Abstract] [Full Text] [Related]
16. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With prostate cancer.
Shah NJ; Patel VG; Zhong X; Pina L; Hawley JE; Lin E; Gartrell BA; Febles VA; Wise DR; Qin Q; Mellgard G; Joshi H; Nauseef JT; Green DA; Vlachostergios PJ; Kwon DH; Huang F; Liaw B; Tagawa S; Kantoff P; Morris MJ; Oh WK
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35657341
[TBL] [Abstract] [Full Text] [Related]
17. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract] [Full Text] [Related]
18. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB
JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754
[TBL] [Abstract] [Full Text] [Related]
19. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract] [Full Text] [Related]
20. Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic prostate cancer Organoids.
Lee S; Mendoza TR; Burner DN; Muldong MT; Wu CCN; Arreola-Villanueva C; Zuniga A; Greenburg O; Zhu WY; Murtadha J; Koutouan E; Pineda N; Pham H; Kang SG; Kim HT; Pineda G; Lennon KM; Cacalano NA; Jamieson CHM; Kane CJ; Kulidjian AA; Gaasterland T; Jamieson CAM
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328625
[TBL] [Abstract] [Full Text] [Related]
[Next]
